Effects of artesunate on the inhibition of hepatic fibrosis through ceramide synthase-ceramide pathway

doi:10.12047/j.cjap.5931.2020.061

Abstract

Abstract: Objective: To investigate the effects of ceramide pathway on the inhibition of artesunate (Art) to hepatic fibrosis.Methods: LX-2 cells were divided into control group, Art treated group with 350 μmol/L, fumonisin B1 (FB1) treated group with 6 μmol/L, and Co-administration group of artesunate 350 μmol/L and fumonisin B1 6 μmol/L. There were 7 compound holes in each group. After 24 hours of treatment, the cells and supernatant were collected and detected. The expressions of homo sapiens longevity assurance homologue 2 (LASS2), peroxisome proliferators-activated receptors-γ (PPAR-γ) and Caspase-3 were evaluated by Western blot, the content of ceramide was evaluated by HPLC-FLD method, MTT assay was adopted to measure the rate of proliferation of LX-2 cells. The content of hydroxyproline was determined by digestive method. Results: Compared with the control group, the expression of ceramide synthase protein and the ceramide content were increased significantly, the proliferation of LX-2 cells was inhibited significantly, the expressions of PPAR-γ and Caspase-3 protein were up-regulated and the secretion of hydroxyproline was inhibited in Art treated group (P＜0.05). In FB1 treated group, the protein expression of ceramide synthase and the ceramide content were decreased significantly, the proliferation of LX-2 cells was increased significantly, the expressions of PPAR-γ and Caspase-3 protein were down-regulated, and the secretion of hydroxyproline was increased (P＜0.05). Compared with the Art alone group, the combination of the two drugs could significantly reduce the effects of Art on the expression of ceramide synthase protein and the increase of ceramide content, and attenuate the effects of Art on the cell proliferation , PPAR-γ, Caspase-3 protein expression and hydroxyproline level of LX-2 cells (P＜0.05). Conclusion: Artesunate could inhibit hepatic fibrosis by increasing the content of ceramide through the ceramide synthase-ceramide pathway.

Key words: hepatic fibrosis, ceramide, synthase-ceramide, artesunate, LX-2

CLC Number:

R575.2

RUAN Jian-jia, DU Yan. Effects of artesunate on the inhibition of hepatic fibrosis through ceramide synthase-ceramide pathway[J]. CJAP, 2020, 36(3): 279-282.

References

[1] Zhang X, Tan Z, Wang Y, et al. PTPRO-associated hepatic stellate cell activation plays a critical role in liver fibrosis[J]. Cell Physiol and Biochem, 2015, 35(3): 885-898.
[2] Zhu W, Wang X, Zhou Y, et al. C2-ceramide induces cell death and protective autophagy in head and neck squamous cell carcinoma cells[J]. Int J Mol Sci, 2014, 15 (2): 3336-3355.
[3] Mencarelli C, Martinez-Martinez P. Ceramide function in the brain: when a slight tilt is enough[J]. Cell Mol Life Sci, 2013, 70 (2): 181-203.
[4] Yang L, Zheng L, Tian Y, et al. C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: A mechanism study[J]. Exp Cell Res, 2015, 332(1): 47-59.
[5] 娄婷婷, 李英娴, 方步武, 等. 测定生物样本中神经酰胺含量的HPLC-FLD法[J]. 药物分析杂志, 2012, 32(10): 1807-1812.
[6] 杜岩, 李立楠, 方步武. 青蒿琥酯抑制肝纤维化的作用及其机制[J]. 中国应用生理学杂志, 2015, 31(1): 14-17.
[7] Schiffmann S, Birod K, Mannich J, et al. Ceramide metabolism in mouse tissue[J]. Int J Biochem Cell Biol, 2013, 45(8): 1886-1894.
[8] Pewzner-Jung Y , Park H , Laviad EL , et al. A critical role for ceramide synthase 2 in liver homeostasis: I. Alterations in lipid metabolic pathways[J]. J Biol Chem, 2010, 285(14): 10902-10910.
[9] Larsen PJ, Tennagels N. On ceramides, other sphingolipids and impaired glucose homeostasis[J]. Mol Metab, 2014, 3(3): 252-260.
[10]Zhang F, Kong D, Lu Y, et al. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside[J]. Cell Mol Life Sci, 2013, 70(2): 259-276.
[11]Wang Z, Xu JP, Zheng YC, et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats[J]. Hepatobiliary Pancreat Dis Int, 2011, 10(1): 64-71.
[12]Li Y, Dong J, Ding T, et al. Sphingomyelin synthase 2 activity and liver steatosis an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression[J]. Arterioscler Thromb Vasc Biol, 2013, 33(7): 1513-1520.
[13]Yu J, Shen BO, Chu ESH, et al. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro[J]. Hepatology, 2010, 51(6): 2008-2019.